PUBLISHER: The Business Research Company | PRODUCT CODE: 1946551
PUBLISHER: The Business Research Company | PRODUCT CODE: 1946551
Minimally invasive glaucoma surgery (MIGS) devices are medical tools designed to lower intraocular pressure (IOP) in glaucoma patients using less invasive techniques compared to traditional glaucoma surgeries. These devices aim to reduce complications, shorten recovery times, and improve patient outcomes by providing a safer, less invasive surgical option for managing glaucoma.
The main types of MIGS devices include valves, glaucoma drainage implants, glaucoma tube shunts, stents, and others. A glaucoma drainage implant, also known as an aqueous shunt or tube shunt, is a small device surgically placed in the eye to treat glaucoma. These devices are used in various surgeries, such as those for glaucoma combined with cataracts or stand-alone glaucoma procedures, targeting areas such as the trabecular meshwork and suprachoroidal space. They are distributed through various channels, including direct tender and retail sales, and are utilized by end users such as ophthalmology clinics and ambulatory surgery centers (ASCs).
Tariffs have influenced the minimally invasive glaucoma surgery devices market by increasing costs for imported micro-implants, precision components, and specialized surgical instruments. These effects are most pronounced in north america and asia-pacific, where many MIGS devices are manufactured or sourced internationally. Higher device costs have impacted pricing strategies for ophthalmology clinics and ambulatory surgery centers. At the same time, tariffs have encouraged localized manufacturing, supplier diversification, and regional assembly of MIGS devices, supporting long-term supply stability.
The minimally invasive glaucoma surgery (migs) devices market research report is one of a series of new reports from The Business Research Company that provides minimally invasive glaucoma surgery (migs) devices market statistics, including minimally invasive glaucoma surgery (migs) devices industry global market size, regional shares, competitors with a minimally invasive glaucoma surgery (migs) devices market share, detailed minimally invasive glaucoma surgery (migs) devices market segments, market trends and opportunities, and any further data you may need to thrive in the minimally invasive glaucoma surgery (migs) devices industry. This minimally invasive glaucoma surgery (migs) devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The minimally invasive glaucoma surgery (migs) devices market size has grown exponentially in recent years. It will grow from $0.89 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 28.1%. The growth in the historic period can be attributed to increasing prevalence of glaucoma, growing aging population, limitations of conventional glaucoma surgeries, rising awareness of vision preservation, increasing adoption of cataract surgeries.
The minimally invasive glaucoma surgery (migs) devices market size is expected to see exponential growth in the next few years. It will grow to $2.79 billion in 2030 at a compound annual growth rate (CAGR) of 24.9%. The growth in the forecast period can be attributed to expanding glaucoma patient pool, growing acceptance of minimally invasive surgical options, rising demand for outpatient ophthalmic procedures, increasing focus on quality-of-life outcomes, expanding access to specialized ophthalmology clinics. Major trends in the forecast period include rising adoption of minimally invasive glaucoma procedures, growing preference for MIGS in early and moderate glaucoma, increasing use of MIGS in combination with cataract surgery, expansion of outpatient and ambulatory glaucoma surgeries, growing demand for safer and faster-recovery glaucoma treatments.
The increasing prevalence of eye disorders is anticipated to drive the growth of minimally invasive glaucoma surgery (MIGS) devices in the future. Eye disorders cover a wide range of conditions affecting the eyes and vision, with their prevalence rising due to lifestyle changes, environmental factors, and aging populations. MIGS devices are innovative tools used to manage various eye diseases, primarily by reducing intraocular pressure (IOP) to prevent or control the progression of glaucoma. For example, according to the National Eye Institute, a US-based government agency, approximately 2.2 million Americans will be blind or partially blind by 2030. Consequently, the growing prevalence of eye disorders is propelling the MIGS devices market.
Leading companies in the minimally invasive glaucoma surgery (MIGS) devices market are focusing on developing advanced solutions, such as sustained-release drug-delivery implants, to replace conventional topical glaucoma treatments. A sustained-release implant is a device that delivers medication continuously over time, improving patient adherence, reducing dosing frequency, and enhancing treatment effectiveness. For example, in February 2024, Celanese Corporation, a US-based specialty materials company, partnered with Glaukos to commercially launch the iDose(R) TR (Travoprost Intracameral Implant) using Celanese's VitalDose(R) Ethylene Vinyl Acetate (EVA) platform. This innovation replaces traditional eye-drop regimens by providing continuous intraocular delivery of travoprost directly to the eye over several months. Integrated with Glaukos' MIGS portfolio, it offers a minimally invasive treatment option that reduces the need for daily eye drops, improves patient compliance, and supports sustained intraocular pressure control, ultimately enhancing long-term therapeutic outcomes.
In July 2024, Alcon Inc., a Switzerland-based medical device company, acquired BELKIN Vision Inc. for $81 million. This strategic acquisition is intended to boost the global adoption of Direct Selective Laser Trabeculoplasty (DSLT) as a first-line treatment for glaucoma. BELKIN Vision Inc., an Israel-based medical device company, specializes in developing and manufacturing laser therapy devices for glaucoma treatment.
Major companies operating in the minimally invasive glaucoma surgery (migs) devices market are Glaukos Corporation, Sight Sciences Inc., Alcon Inc., Johnson & Johnson Vision Care Inc., Bausch & Lomb Incorporated, Carl Zeiss Meditec AG, Nova Eye Medical Limited, iSTAR Medical SA, New World Medical Inc., MicroSurgical Technology Inc., ASICO LLC, Ziemer Ophthalmic Systems AG, Ellex Medical Lasers Ltd., Lumenis Ltd., Iridex Corporation, Katena Products Inc., Oertli Instrumente AG, Sifi S.p.A., Aquesys Inc., Beaver-Visitec International
North America was the largest region in the minimally invasive glaucoma surgery (MIGS) devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimally invasive glaucoma surgery (migs) devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the minimally invasive glaucoma surgery (migs) devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The minimally invasive glaucoma surgery (MIGS) devices market consists of revenues earned by entities by providing canal-based procedures, viscocanalostomy, and canaloplasty procedures. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimally invasive glaucoma surgery (MIGS) devices market also includes sales of glaucoma drainage implants, glaucoma tube shunts, and invasive devices. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Minimally Invasive Glaucoma Surgery (MIGS) Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses minimally invasive glaucoma surgery (migs) devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for minimally invasive glaucoma surgery (migs) devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The minimally invasive glaucoma surgery (migs) devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.